Abstract 488P
Background
Glioma, the most common malignancy of the central nervous system, is charactarised by its extensive proliferation and invasion. An increasing number of studies suggest that glioma stem cells (GSCs) are at the root of glioma's difficulty in control, treatment and recurrence. The adhesion molecule integrin α2 (ITGA2) plays an important role in regulating various biological behaviors such as cell migration, growth and differentiation. Previous studies have shown that ITGA2 is closely associated with tumor progression, but the role and mechanism of ITGA2 in regulating glioma progression and stemness remain unclear.
Methods
The gene expression profile of GSCs was analyzed by RNA-seq. ITGA2 expression in glioma tissues was examined by immunohistochemical staining, followed by analysis of the correlation between ITGA2 expression and clinical features. In addition, the effects of lentivirus-mediated RNA interference of ITGA2 on cell proliferation, cell migration, spheroid forming ability and cell stemness specific gene and protein expression in glioma cells were investigated.
Results
The expression level of ITGA2 was significantly increased in GSCs compared to glioma cells. ITGA2 protein expression was increased in high-grade glioma samples. Prognostic analysis showed that patients with high ITGA2 expression had shorter survival. In glioma cells, knockdown of ITGA2 significantly inhibited the proliferation, migration, invasion and spheroid forming ability of glioma cells. TCGA data analysis showed that ITGA2 expression positively correlated with the expression of stem cell-specific genes in gliomas. Knockdown of ITGA2 significantly reduced the expression levels of stem cell-specific genes and proteins in the cells. The molecular mechanism revealed that ITGA2 knockdown inhibited the activation of the AKT signaling pathway. The AKT phosphorylation activator SC79 reversed the reduced sphere-forming ability of glioma cells and the reduced expression levels of stem cell-specific genes and proteins in cells caused by ITGA2 knockdown.
Conclusions
Our findings elucidate the role and molecular mechanism of ITGA2 in regulating glioma progression and stemness, and provide new ideas for basic glioma research and tumor treatment strategies targeting GSCs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
566P - Impact of weekly irinotecan’s cycles during preoperative chemoradiotherpy in locally advanced rectal cancer: A post-hoc analysis of the CinClare study
Presenter: Ji Zhu
Session: Poster session 16
567P - Interim endoscopic restaging after induction chemotherapy to predict complete response and survival after total neoadjuvant therapy in low rectal cancer: Ad-hoc analysis of the IMPACT trial
Presenter: Eiji Shinozaki
Session: Poster session 16
568P - Risk factors for recurrence after surgery for rectal cancer in a modern, nationwide population-based cohort
Presenter: Sepehr Doroudian
Session: Poster session 16
569P - Mismatch repair deficient, stage II/III rectal cancer: Real-world patient, tumour, and treatment characteristics in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
571P - Neoadjuvant chemotherapy with FOLFIRINOX and short course radiotherapy in locally advanced rectal caner (ISANOX): A prospective phase II trial
Presenter: Feryel Letaief-Ksontini
Session: Poster session 16
572P - Tolerance of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34 – FFCD 1402 - ADAGE randomized phase III trial
Presenter: Thomas Aparicio
Session: Poster session 16
573P - M9140, an anti-CEACAM5 antibody drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): Updated results from a phase I trial
Presenter: Valentina Boni
Session: Poster session 16
574P - First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study
Presenter: Zhen Yu Lin
Session: Poster session 16
575P - Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results
Presenter: Andrew Hendifar
Session: Poster session 16